US 12,070,461 B2
Methods and formulations for modulating Lyn kinase activity and treating related disorders
Andrew G. Reaume, Exton, PA (US); and Michael S. Saporito, Exton, PA (US)
Assigned to Melior Pharmaceuticals I, Inc., Exton, PA (US)
Filed by Melior Pharmaceuticals I, Inc., Exton, PA (US)
Filed on May 7, 2021, as Appl. No. 17/314,543.
Application 17/314,543 is a continuation of application No. 16/286,976, filed on Feb. 27, 2019, granted, now 11,033,548.
Application 16/286,976 is a continuation of application No. 15/684,130, filed on Aug. 23, 2017, granted, now 10,251,883, issued on Apr. 9, 2019.
Application 15/684,130 is a continuation of application No. 14/941,473, filed on Nov. 13, 2015, granted, now 9,763,945, issued on Sep. 19, 2017.
Application 14/941,473 is a continuation of application No. 14/182,380, filed on Feb. 18, 2014, granted, now 9,216,959, issued on Dec. 22, 2015.
Application 14/182,380 is a continuation of application No. 13/690,548, filed on Nov. 30, 2012, granted, now 8,835,448, issued on Sep. 16, 2014.
Application 13/690,548 is a continuation of application No. 12/837,067, filed on Jul. 15, 2010, granted, now 8,343,985, issued on Jan. 1, 2013.
Application 12/837,067 is a continuation of application No. 11/507,652, filed on Aug. 22, 2006, granted, now 7,776,870, issued on Aug. 17, 2010.
Claims priority of provisional application 60/808,533, filed on May 26, 2006.
Claims priority of provisional application 60/709,798, filed on Aug. 22, 2005.
Prior Publication US 2021/0361652 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/513 (2006.01); A61K 9/00 (2006.01); A61K 31/425 (2006.01); A61K 31/495 (2006.01); A61K 31/498 (2006.01); A61K 31/505 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); C07D 239/52 (2006.01)
CPC A61K 31/513 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 31/495 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07D 239/52 (2013.01); A61K 31/425 (2013.01); A61K 31/498 (2013.01); A61K 31/505 (2013.01)] 16 Claims
 
1. A method of treating gestational diabetes mellitus (GDM) or maturity onset diabetes of the young (MODY) in a mammal comprising administering to the mammal in need thereof a compound of formula:

OG Complex Work Unit Chemistry
wherein:
R1 is an alkyl group;
X is a halogen;
Y is O, S, or NH;
Z is O or S; and
n is an integer from 0 to 5 and m is 0 or 1, wherein m+n is less than or equal to 5,
or a pharmaceutically acceptable salt thereof,
wherein the compound is administered concurrently with the administration of another therapeutic agent chosen from a statin, a PPAR agonist, a bile-acid-binding resin, niacin, nicotinic acid, a RXR agonist, an anti-obesity drug, a hormone, an insulin secretagog, a tyrophostine, a sulfonylurea-based drug, metformin, an α-glucosidase inhibitor, an apo A-I agonist, apolipoprotein E, a cardiovascular drug, and a chemotherapeutic agent.